Solid tumor
-
【Product for Licensing】A Highly Differentiated EGFR x HER2 Bispecific ADC for Targeted Therapy of Multiple Types of Solid Tumors
If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn
-
Radionetics Oncology Enters Into Strategic Agreement With Lilly on its proprietary GPCR targeting small molecule radiopharmaceuticals
Warmest congratulations to Eli Lilly and Radionetics Oncology!
-
【Product Wanted】HER2 Small Molecules That Can Penetrate BBB
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
-
【Product for Licensing】ANTI-CDCP1 mAb and ADC
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. We will discuss with you and may present the non-confidential deck to you for review asap.
-
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Congratulations to Day One Biopharmaceuticals and MabCare Therapeutics!
-
【ASCO Highlights】China-made First-in-Class Claudin 18.2 CAR-T Therapy Shows Promising Phase I Results!
Follow Drug Times to grasp valuable industry information at the first moment
